{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:29Z","timestamp":1792784909018,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004809","name":"FINEP","doi-asserted-by":"crossref","award":["01.20.0009.00"],"award-info":[{"award-number":["01.20.0009.00"]}],"id":[{"id":"10.13039\/501100004809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["403701\/2020-1, 403520\/2020-7, 408518\/2022-7"],"award-info":[{"award-number":["403701\/2020-1, 403520\/2020-7, 408518\/2022-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DECEIIS\/SECTICS\/MS","award":["25000.177752\/2022-11"],"award-info":[{"award-number":["25000.177752\/2022-11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01407-x","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:15:47Z","timestamp":1772594147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An innovative nasal nanovaccine against SARS-CoV-2 induces systemic and upper airway immunity controlling viral replication"],"prefix":"10.1038","volume":"11","author":[{"given":"Roberta L.","family":"Pagni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edecio","family":"Cunha-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin da","family":"Silva Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edilberto","family":"Post\u00f3l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Elaine de","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonnatan J.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamires L.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela P.","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos C.","family":"Knirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo S.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio H.","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koiti","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Remuzgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Cau\u00ea","family":"Jacintho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Maria","family":"Demarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Leite","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Beatriz","family":"Boscardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela S.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Victor","family":"Batalha-Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keity S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonio","family":"Stephano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of COVID-19 Brazil Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia Cristina Kazue Kuramoto","family":"Takara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamille Ramos","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Massao","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia Carnevale","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Rodrigues","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Ribeiro","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar Freschi","family":"de Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Maria","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma Aliotti","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Regina","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Washington Robert","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"1407_CR1","unstructured":"World Health Organization. The top 10 causes of death https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (2020)."},{"key":"1407_CR2","unstructured":"World Health Organization. COVID-19 vaccine tracker and landscape https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (2023)."},{"key":"1407_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"1407_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"1407_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.5471","volume":"251","author":"AR Bourgonje","year":"2020","unstructured":"Bourgonje, A. R. et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J. Pathol. 251, 228\u2013248 (2020).","journal-title":"J. Pathol."},{"key":"1407_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2027160","volume":"18","author":"I Mohammed","year":"2022","unstructured":"Mohammed, I. et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum. Vaccin. Immunother. 18, 2027160 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1407_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/0194599820982633","volume":"164","author":"BS Bleier","year":"2020","unstructured":"Bleier, B. S., Ramanathan, M. & Lane, A. P. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol. Head. Neck Surg. 164, 305\u2013307 (2020).","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"1407_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104402","volume":"87","author":"F Liew","year":"2023","unstructured":"Liew, F. et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine 87, 104402 (2023).","journal-title":"EBioMedicine"},{"key":"1407_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25949-x","volume":"12","author":"J Fr\u00f6berg","year":"2021","unstructured":"Fr\u00f6berg, J. et al. SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms. Nat. Commun. 12, 5621 (2021).","journal-title":"Nat. Commun."},{"key":"1407_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104585","volume":"92","author":"D Pilapitiya","year":"2023","unstructured":"Pilapitiya, D., Wheatley, A. K. & Tan, H.-X. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine 92, 104585 (2023).","journal-title":"EBioMedicine"},{"key":"1407_CR11","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1016\/j.vaccine.2023.05.011","volume":"41","author":"E Kehagia","year":"2023","unstructured":"Kehagia, E., Papakyriakopoulou, P. & Valsami, G. Advances in intranasal vaccine delivery: a promising non-invasive route of immunization. Vaccine 41, 3589\u20133603 (2023).","journal-title":"Vaccine"},{"key":"1407_CR12","first-page":"2003","volume":"328","author":"A Slomski","year":"2022","unstructured":"Slomski, A. Intranasal COVID-19 vaccine disappointing in first-in-human trial. JAMA 328, 2003 (2022).","journal-title":"JAMA"},{"key":"1407_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","volume":"11","author":"F Zhu","year":"2023","unstructured":"Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 1075\u20131088 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1407_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.180784","volume":"9","author":"B Sun","year":"2024","unstructured":"Sun, B. et al. An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA. JCI Insight 9, e180784 (2024).","journal-title":"JCI Insight"},{"key":"1407_CR15","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2411.11059","volume":"35","author":"JB Ndzouboukou","year":"2025","unstructured":"Ndzouboukou, J. B., Kamara, A. A., Ullah, N., Lei, Q. & Fan, X. L. A Meta-analysis on the immunogenicity of homologous versus heterologous immunization regimens against SARS-CoV-2 Beta, Delta, and Omicron BA.1 VoCs in healthy adults. J. Microbiol. Biotechnol. 35, e2411059 (2025).","journal-title":"J. Microbiol. Biotechnol."},{"key":"1407_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/sji.70000","volume":"101","author":"E Nissil\u00e4","year":"2025","unstructured":"Nissil\u00e4, E. et al. The COVID-19 vaccine ChAdOx1 is opsonized by anti-vector antibodies that activate complement and promote viral vector phagocytosis. Scand. J. Immunol. 101, e70000 (2025).","journal-title":"Scand. J. Immunol."},{"key":"1407_CR17","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1021\/acs.accounts.0c00280","volume":"53","author":"Y Yang","year":"2020","unstructured":"Yang, Y., Zhang, M., Song, H. & Yu, C. Silica-based nanoparticles for biomedical applications: from nanocarriers to biomodulators. Acc. Chem. Res. 53, 1545\u20131556 (2020).","journal-title":"Acc. Chem. Res."},{"key":"1407_CR18","unstructured":"Liljenstr\u00f6m, C.L.D.; Finnveden, G. Silicon-Based Nanomaterials in a Life-Cycle Perspective, Including a Case Study on SelfCleaning Coatings https:\/\/www.researchgate.net\/publication\/280264076_Silicon-based_nanomaterials_in_a_life-cycle_perspective_including_a_case_study_on_self-cleaning_coatings (2013)."},{"key":"1407_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.nantod.2013.04.007","volume":"8","author":"L Tang","year":"2013","unstructured":"Tang, L. & Cheng, J. Nonporous silica nanoparticles for nanomedicine application. Nano Today 8, 290\u2013312 (2013).","journal-title":"Nano Today"},{"key":"1407_CR20","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41578-021-00385-x","volume":"6","author":"TI Janjua","year":"2021","unstructured":"Janjua, T. I., Cao, Y., Yu, C. & Popat, A. Clinical translation of silica nanoparticles. Nat. Rev. Mater. 6, 1072\u20131074 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1407_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s13346-013-0172-9","volume":"4","author":"A Tan","year":"2014","unstructured":"Tan, A., Eskandar, N. G., Rao, S. & Prestidge, C. A. First in man bioavailability and tolerability studies of a silica\u2013lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen. Drug Deliv. Transl. Res. 4, 212\u2013221 (2014).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1407_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s13346-020-00853-x","volume":"11","author":"TR Meola","year":"2021","unstructured":"Meola, T. R., Abuhelwa, A. Y., Joyce, P., Clifton, P. & Prestidge, C. A. A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. Drug Deliv. Transl. Res. 11, 1261\u20131272 (2021).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1407_CR23","doi-asserted-by":"publisher","first-page":"e29424","DOI":"10.1371\/journal.pone.0029424","volume":"7","author":"F Barandeh","year":"2012","unstructured":"Barandeh, F. et al. Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo. PLoS ONE 7, e29424 (2012).","journal-title":"PLoS ONE"},{"key":"1407_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1163\/156855207779768214","volume":"18","author":"SC Brown","year":"2007","unstructured":"Brown, S. C. et al. Influence of shape, adhesion and simulated lung mechanics on amorphous silica nanoparticle toxicity. Adv. Powder Technol. 18, 69\u201379 (2007).","journal-title":"Adv. Powder Technol."},{"key":"1407_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.tox.2012.02.001","volume":"294","author":"C Fruijtier-P\u00f6lloth","year":"2012","unstructured":"Fruijtier-P\u00f6lloth, C. The toxicological mode of action and the safety of synthetic amorphous silica-a nanostructured material. Toxicology 294, 61\u201379 (2012).","journal-title":"Toxicology"},{"key":"1407_CR26","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1021\/nn2043803","volume":"6","author":"T Yu","year":"2012","unstructured":"Yu, T., Greish, K., McGill, L. D., Ray, A. & Ghandehari, H. Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS Nano 6, 2289\u20132301 (2012).","journal-title":"ACS Nano"},{"key":"1407_CR27","unstructured":"European Medicines Agency, Scientific Committee on Consumer Safety opinion on silica, hydrated silica, and silica surface modified with alkyl silicates (nano form) https:\/\/ec.europa.eu\/health\/scientific_committees\/consumer_safety\/docs\/sccs_o_175.pdf (2015)."},{"key":"1407_CR28","unstructured":"U.S Food and Drug Administration, US Food and Drug Administration GRAS Substances (SCOGS) Database\u2014Select Committee on GRAS Substances (SCOGS) Opinion: Silicates, (n.d.) https:\/\/www.fda.gov\/food\/generally-recognized-safe-gras\/gras-substances-scogs-database (2022)."},{"key":"1407_CR29","unstructured":"FDA, 2023 U.S. FDA Drug Master Files (DMF) 1Q2023 https:\/\/www.fda.gov\/media\/166951\/download (2023)."},{"key":"1407_CR30","unstructured":"EMA, 2017 Cyclodextrins used as excipients. Report published in support of the \u2018Questions and answers on cyclodextrins used as excipients in medicinal products for human use\u2019 (EMA\/CHMP\/495747\/2013) https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-and-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf (2017)."},{"key":"1407_CR31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics13081180","volume":"13","author":"G Rassu","year":"2021","unstructured":"Rassu, G. et al. Versatile nasal application of cyclodextrins: excipients and\/or actives. Pharmaceutics 13, 1180 (2021).","journal-title":"Pharmaceutics"},{"key":"1407_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/10611869808997878","volume":"6","author":"E Marttin","year":"1998","unstructured":"Marttin, E., Verhoef, J. C. & Merkus, F. W. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 6, 17\u201336 (1998).","journal-title":"J. Drug Target."},{"key":"1407_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jcis.2018.07.062","volume":"531","author":"MH Asim","year":"2018","unstructured":"Asim, M. H. et al. S-protected thiolated cyclodextrins as mucoadhesive oligomers for drug delivery. J. Colloid Interface Sci. 531, 261\u2013268 (2018).","journal-title":"J. Colloid Interface Sci."},{"key":"1407_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","volume":"535","author":"P Jansook","year":"2018","unstructured":"Jansook, P., Ogawa, N. & Loftsson, T. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int. J. Pharm. 535, 272\u2013284 (2018).","journal-title":"Int. J. Pharm."},{"key":"1407_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/scipharm87040033","volume":"87","author":"A Haimhoffer","year":"2019","unstructured":"Haimhoffer, A. et al. Cyclodextrins in drug delivery systems and their effects on biological barriers. Sci. Pharm. 87, 33 (2019).","journal-title":"Sci. Pharm."},{"key":"1407_CR36","doi-asserted-by":"publisher","first-page":"e00497","DOI":"10.1128\/mSphere.00497-18","volume":"3","author":"FL Matassoli","year":"2018","unstructured":"Matassoli, F. L. et al. Hydroxypropyl-beta-cyclodextrin reduces inflammatory signaling from monocytes: possible implications for suppression of HIV chronic immune activation. mSphere 3, e00497\u201318 (2018).","journal-title":"mSphere"},{"key":"1407_CR37","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/ijms25042061","volume":"25","author":"A Lu","year":"2024","unstructured":"Lu, A. et al. Hydroxypropyl-beta cyclodextrin barrier prevents respiratory viral infections: a preclinical study. Int. J. Mol. Sci. 25, 2061 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1407_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-5173(02)00345-9","volume":"246","author":"K Asai","year":"2002","unstructured":"Asai, K. et al. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int. J. Pharm. 246, 25\u201335 (2002).","journal-title":"Int. J. Pharm."},{"key":"1407_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0378-5173(99)00342-7","volume":"193","author":"RU Agu","year":"2000","unstructured":"Agu, R. U. et al. Safety assessment of selected cyclodextrin-effect of ciliary activity using a human cell suspension culture model exhibiting in-vitro ciliogenesis. Int. J. Pharm. 193, 219\u2013226 (2000).","journal-title":"Int. J. Pharm."},{"key":"1407_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bbrc.2020.10.012","volume":"538","author":"M Yuan","year":"2021","unstructured":"Yuan, M., Liu, H., Wu, N. C. & Wilson, I. A. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem. Biophys. Res. Commun. 538, 192\u2013203 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1407_CR41","first-page":"112","volume":"1","author":"ER Fernandes","year":"2022","unstructured":"Fernandes, E. R. et al. Time-dependent contraction of the SARS-CoV-2-specific T-cell responses in convalescent individuals. JACI Glob. 1, 112\u2013121 (2022).","journal-title":"JACI Glob."},{"key":"1407_CR42","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1128\/JVI.79.5.2910-2919.2005","volume":"79","author":"T Ichinohe","year":"2005","unstructured":"Ichinohe, T. et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79, 2910\u20132919 (2005).","journal-title":"J. Virol."},{"key":"1407_CR43","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s11095-006-0206-9","volume":"23","author":"BR Sloat","year":"2006","unstructured":"Sloat, B. R. & Cui, Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid-induced strong mucosal and systemic immunities. Pharm. Res. 23, 1217\u20131226 (2006).","journal-title":"Pharm. Res."},{"key":"1407_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejpb.2015.11.003","volume":"98","author":"K Netsomboon","year":"2016","unstructured":"Netsomboon, K. & Bernkop-Schn\u00fcrch, A. Mucoadhesive vs. mucopenetrating particulate drug delivery. Eur. J. Pharm. Biopharm. 98, 76\u201389 (2016).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"1407_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1574-695X.2007.00359.x","volume":"52","author":"SC Corr","year":"2008","unstructured":"Corr, S. C., Gahan, C. C. G. M. & Hill, C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol. 52, 2\u201312 (2008).","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"1407_CR46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nri1439","volume":"4","author":"H Kiyono","year":"2004","unstructured":"Kiyono, H. & Fukuyama, S. NALT- versus Peyer\u2019s-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4, 699\u2013710 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"1407_CR47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/1753425917738331","volume":"23","author":"DM G\u00f3mez","year":"2017","unstructured":"G\u00f3mez, D. M., Urcuqui-Inchima, S. & Hernandez, J. C. Silica nanoparticles induce NLRP3 inflammasome activation in human primary immune cells. Innate Immun. 23, 697\u2013708 (2017).","journal-title":"Innate Immun."},{"key":"1407_CR48","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1021\/nn300149c","volume":"6","author":"L Tang","year":"2012","unstructured":"Tang, L., Fan, T. M., Borst, L. B. & Cheng, J. Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. ACS Nano 6, 3954\u20133966 (2012).","journal-title":"ACS Nano"},{"key":"1407_CR49","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.bbrc.2012.09.095","volume":"427","author":"T Hirai","year":"2012","unstructured":"Hirai, T. et al. Amorphous silica nanoparticles enhance cross-presentation in murine dendritic cells. Biochem. Biophys. Res. Commun. 427, 553\u2013556 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1407_CR50","doi-asserted-by":"publisher","first-page":"10843","DOI":"10.1021\/acsnano.8b03363","volume":"12","author":"B Vis","year":"2018","unstructured":"Vis, B. et al. Non-functionalized ultrasmall silica nanoparticles directly and size-selectively activate T cells. ACS Nano 12, 10843\u201310854 (2018).","journal-title":"ACS Nano"},{"key":"1407_CR51","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.4049\/jimmunol.1402027","volume":"194","author":"M Onishi","year":"2015","unstructured":"Onishi, M. et al. Hydroxypropyl-beta-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen. J. Immunol. 194, 2673\u20132682 (2015).","journal-title":"J. Immunol."},{"key":"1407_CR52","doi-asserted-by":"publisher","first-page":"587012","DOI":"10.3389\/fmolb.2020.587012","volume":"7","author":"G Sanit\u00e0","year":"2020","unstructured":"Sanit\u00e0, G., Carrese, B. & Lamberti, A. Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization. Front. Mol. Biosci. 7, 587012 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"1407_CR53","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1126\/science.1223012","volume":"337","author":"B Button","year":"2012","unstructured":"Button, B. et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337, 937\u2013941 (2012).","journal-title":"Science"},{"key":"1407_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10814-9","volume":"10","author":"WAA de Steenhuijsen Piters","year":"2019","unstructured":"de Steenhuijsen Piters, W. A. A. et al. Interaction between the nasal microbiota and S. pneumoniae in the context of live-attenuated influenza vaccine. Nat. Commun. 10, 2981 (2019). 9.","journal-title":"Nat. Commun."},{"key":"1407_CR55","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1128\/IAI.00681-10","volume":"78","author":"X Liu","year":"2010","unstructured":"Liu, X., Wetzler, L. M., Nascimento, L. O. & Massari, P. Human airway epithelial cell responses to Neisseria lactamica and purified porin via Toll-like receptor 2-dependent signaling. Infect. Immun. 78, 5314\u20135323 (2010).","journal-title":"Infect. Immun."},{"key":"1407_CR56","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/cells11081324","volume":"11","author":"C de Fays","year":"2022","unstructured":"de Fays, C., Carlier, F. M., Gohy, S. & Pilette, C. Secretory immunoglobulin A immunity in chronic obstructive respiratory diseases. Cells 11, 1324 (2022).","journal-title":"Cells"},{"key":"1407_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21039-z","volume":"8","author":"C Firacative","year":"2018","unstructured":"Firacative, C. et al. Identification of T helper (Th)1- and Th2-associated antigens of Cryptococcus neoformans in a murine model of pulmonary infection. Sci. Rep. 8, 2681 (2018).","journal-title":"Sci. Rep."},{"key":"1407_CR58","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41577-020-00471-1","volume":"20","author":"DS Khoury","year":"2020","unstructured":"Khoury, D. S. et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat. Rev. Immunol. 20, 727\u2013738; 1 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1407_CR59","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.medidd.2021.100110","volume":"12","author":"C Liu","year":"2021","unstructured":"Liu, C., Jiang, X., Gan, Y. & Yu, M. Engineering nanoparticles to overcome the mucus barrier for drug delivery: design, evaluation and state-of-the-art. Med. Drug Discov. 12, 100110 (2021).","journal-title":"Med. Drug Discov."},{"key":"1407_CR60","first-page":"255","volume":"12","author":"S Honary","year":"2013","unstructured":"Honary, S. & Zahir, F. Effect of zeta potential on the properties of nano-drug delivery systems - A review (Part 1). Trop. J. Pharm. Res. 12, 255\u2013264 (2013).","journal-title":"Trop. J. Pharm. Res."},{"key":"1407_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-018-2728-6","volume":"13","author":"P Foroozandeh","year":"2018","unstructured":"Foroozandeh, P. & Aziz, A. A. Insight into cellular uptake and intracellular trafficking of nanoparticles. Nanoscale Res. Lett. 13, 339 (2018).","journal-title":"Nanoscale Res. Lett."},{"key":"1407_CR62","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.addr.2017.12.002","volume":"124","author":"JM Newby","year":"2018","unstructured":"Newby, J. M. et al. Technologies strategies to estimate and control diffuse passage times through the mucus barrier in mucosal drug delivery. Adv. Drug Deliv. Rev. 124, 64\u201381 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1407_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jconrel.2016.02.043","volume":"228","author":"M Li","year":"2016","unstructured":"Li, M. et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J. Control. Release 228, 9\u201319 (2016).","journal-title":"J. Control. Release"},{"key":"1407_CR64","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.nano.2015.07.004","volume":"11","author":"L Li","year":"2015","unstructured":"Li, L. et al. Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape. Nanomedicine 11, 1915\u20131924 (2015).","journal-title":"Nanomedicine"},{"key":"1407_CR65","doi-asserted-by":"publisher","first-page":"9597","DOI":"10.1021\/ac801882g","volume":"80","author":"XX He","year":"2008","unstructured":"He, X. X. et al. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Analy. Chem. 80, 9597\u20139603 (2008).","journal-title":"Analy. Chem."},{"key":"1407_CR66","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/nbt1340","volume":"25","author":"HS Choi","year":"2009","unstructured":"Choi, H. S. et al. Renal clearance of nanoparticles. Nat. Biotechnol. 25, 1165\u20131170 (2009).","journal-title":"Nat. Biotechnol."},{"key":"1407_CR67","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.cis.2015.10.002","volume":"225","author":"DQ Arick","year":"2015","unstructured":"Arick, D. Q., Choi, Y. H., Kim, H. C. & Won, Y.-Y. Effects of nanoparticles on the mechanical functioning of the lung. Adv. Colloid Interface Sci. 225, 218\u2013228 (2015).","journal-title":"Adv. Colloid Interface Sci."},{"key":"1407_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jconrel.2020.03.009","volume":"322","author":"X Gu","year":"2020","unstructured":"Gu, X. et al. Clearance of two organic nanoparticles from the brain via the paravascular pathway. J. Control. Rel. 322, 31\u201341 (2020).","journal-title":"J. Control. Rel."},{"key":"1407_CR69","doi-asserted-by":"publisher","first-page":"101631","DOI":"10.1016\/j.apmt.2022.101631","volume":"29","author":"ML Formica","year":"2022","unstructured":"Formica, M. L. et al. On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Appl. Mater. Today 29, 101631 (2022).","journal-title":"Appl. Mater. Today"},{"key":"1407_CR70","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejps.2018.12.001","volume":"128","author":"I Hajdu","year":"2019","unstructured":"Hajdu, I. et al. Radiochemical synthesis and preclinical evaluation of 68Ga-labeled NODAGA-hydroxypropyl-beta-cyclodextrin (68Ga-NODAGA-HPBCD). Eur. J. Pharm. Sci. 128, 202\u2013208 (2019).","journal-title":"Eur. J. Pharm. Sci."},{"key":"1407_CR71","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","volume":"71","author":"NJ Carter","year":"2011","unstructured":"Carter, N. J. & Curran, M. P. Live attenuated influenza vaccine (Flumist; Fluenz): a review of its use in prevention of seasonal influenza in children and adults. Drugs 71, 1591\u20131622 (2011).","journal-title":"Drugs"},{"key":"1407_CR72","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","volume":"350","author":"M Mutsch","year":"2004","unstructured":"Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland. N. Engl. J. Med. 350, 896\u2013903 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1407_CR73","doi-asserted-by":"publisher","first-page":"104298","DOI":"10.1016\/j.ebiom.2022.104298","volume":"85","author":"M Madhavan","year":"2022","unstructured":"Madhavan, M. et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. EBioMedicine 85, 104298 (2022).","journal-title":"EBioMedicine"},{"key":"1407_CR74","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.nano.2014.08.004","volume":"11","author":"KB Knudsen","year":"2015","unstructured":"Knudsen, K. B. et al. In vivo toxicity of cationic micelles and liposomes. Nanomedicine 11, 467\u2013477 (2015).","journal-title":"Nanomedicine"},{"key":"1407_CR75","first-page":"8480","volume":"9","author":"P Zhang","year":"2015","unstructured":"Zhang, P. et al. Nanoparticle size influences antigen retention and presentation in lymph node. ACS Nano 9, 8480\u20138493 (2015).","journal-title":"ACS Nano"},{"key":"1407_CR76","doi-asserted-by":"publisher","first-page":"L833","DOI":"10.1152\/ajplung.00173.2001","volume":"282","author":"DS Southam","year":"2002","unstructured":"Southam, D. S., Dolovich, M., O\u2019Byrne, P. M. & Inman, M. D. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L833\u2013L839 (2002).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1407_CR77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101\u2013124 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1407_CR78","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/mi.2012.93","volume":"6","author":"B Corth\u00e9sy","year":"2013","unstructured":"Corth\u00e9sy, B. Role of secretory IgA in infection and immunity. Mucosal Immunol. 6, 535\u2013542 (2013).","journal-title":"Mucosal Immunol."},{"key":"1407_CR79","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/infdis\/jiac065","volume":"226","author":"PF Wright","year":"2022","unstructured":"Wright, P. F. et al. Longitudinal systemic and mucosal immune response to SARS-CoV-2 infection. J. Infect. Dis. 226, 1204\u20131214 (2022).","journal-title":"J. Infect. Dis."},{"key":"1407_CR80","doi-asserted-by":"publisher","first-page":"eabn1413","DOI":"10.1126\/scitranslmed.abn1413","volume":"14","author":"BL Hartwell","year":"2022","unstructured":"Hartwell, B. L. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci. Transl. Med. 14, eabn1413 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1407_CR81","first-page":"100664","volume":"24","author":"K Adhikari","year":"2025","unstructured":"Adhikari, K. & Verma, S. C. Neutralization antibody responses to SARS-CoV-2 variants after COVID-19 vaccination and boosters. Vaccine 24, 100664 (2025).","journal-title":"Vaccine"},{"key":"1407_CR82","doi-asserted-by":"publisher","first-page":"1346749","DOI":"10.3389\/fimmu.2024.1346749","volume":"15","author":"O Bladh","year":"2024","unstructured":"Bladh, O. et al. Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum. Front. Immunol. 15, 1346749 (2024).","journal-title":"Front. Immunol."},{"key":"1407_CR83","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/vaccines9010013","volume":"9","author":"L Riepler","year":"2020","unstructured":"Riepler, L. et al. Comparison of four SARS-CoV-2 neutralization assays. Vaccines 9, 13 (2020).","journal-title":"Vaccines"},{"key":"1407_CR84","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"1407_CR85","doi-asserted-by":"publisher","first-page":"e0160875","DOI":"10.1371\/journal.pone.0160875","volume":"11","author":"L-Y Huang","year":"2016","unstructured":"Huang, L.-Y., Stuart, C., Takeda, K., D\u2019Agnillo, F. & Golding, B. Poly(I:C) induces human lung endothelial barrier dysfunction by disrupting tight junction expression of claudin-5. PloS One 11, e0160875 (2016).","journal-title":"PloS One"},{"key":"1407_CR86","doi-asserted-by":"publisher","first-page":"e32110","DOI":"10.1371\/journal.pone.0032110","volume":"7","author":"M Starkhammar","year":"2012","unstructured":"Starkhammar, M. et al. Intranasal administration of poly(I:C) and LPS in BALB\/c mice induces airway hyperresponsiveness and inflammation via different pathways. PLoS ONE 7, e32110 (2012).","journal-title":"PLoS ONE"},{"key":"1407_CR87","doi-asserted-by":"crossref","unstructured":"Misra, S. K., Kapoor, A. & Pathak, K. Nanovaccines for Mucosal Immunity (eds Chavda, V. P. & Apostolopoulos, V.) 367\u2013404 (Wiley online library, 2024).","DOI":"10.1002\/9781394175482.ch11"},{"key":"1407_CR88","unstructured":"WHO. Recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration, Annex 4, WHO Technical Report Series No. 977 https:\/\/www.who.int\/publications\/m\/item\/influenza-attenuated-intranasal-administration-annex-4-trs-no-977 (2013)."},{"key":"1407_CR89","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"1407_CR90","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2022","unstructured":"\u0110or\u0111evi\u0107, S. et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv. Transl. Res. 12, 500\u2013525; 2 (2022).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1407_CR91","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0021-9797(68)90272-5","volume":"26","author":"W St\u00f6ber","year":"1968","unstructured":"St\u00f6ber, W., Fink, A. & Bohn, E. Controlled growth of monodisperse silica spheres in the micron size range. J. Colloid Interface Sci. 26, 62\u201369 (1968).","journal-title":"J. Colloid Interface Sci."},{"key":"1407_CR92","unstructured":"Severe Acute Respiratory Syndrome Coronavirus 2 Isolate Wuhan-Hu-1, co-Nucleotide-NCBI. https:\/\/www.ncbi.nlm.nih.gov\/nuccore\/MN908947 (2020)."},{"key":"1407_CR93","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. Universal design of Betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733 (2020).","journal-title":"Cell"},{"key":"1407_CR94","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1002\/cpmc.100","volume":"57","author":"D Stadlbauer","year":"2020","unstructured":"Stadlbauer, D. et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57, e100 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"1407_CR95","doi-asserted-by":"publisher","first-page":"e200342","DOI":"10.1590\/0074-02760200342","volume":"115","author":"DB Ara\u00fajo","year":"2020","unstructured":"Ara\u00fajo, D. B. et al. SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network. Mem. Inst. Oswaldo Cruz 115, e200342 (2020).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"1407_CR96","unstructured":"World Health Organization (WHO). Laboratory Biosafety Guidance Related to the Novel Coronavirus (2019-nCoV). https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/laboratory-biosafety-novelcoronavirus-version-1-1.pdf?sfvrsn=912a9847_2 (WHO, 2020)."},{"key":"1407_CR97","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/ani11030673","volume":"11","author":"AL Whittaker","year":"2021","unstructured":"Whittaker, A. L., Liu, Y. & Barker, T. H. Methods used and application of the mouse Grimace Scale in biomedical research 10 years on: a scoping review. Animals 11, 673 (2021).","journal-title":"Animals"},{"key":"1407_CR98","doi-asserted-by":"publisher","first-page":"e20201181","DOI":"10.1084\/jem.20201181","volume":"217","author":"F Schmidt","year":"2020","unstructured":"Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).","journal-title":"J. Exp. Med."},{"key":"1407_CR99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cpmo.21","volume":"7","author":"PM Quiros","year":"2017","unstructured":"Quiros, P. M., Goyal, A., Jha, P. & Auwerx, J. Analysis of mtDNA\/nDNA ratio in mice. Curr. Protoc. Mouse Biol. 7, 47\u201354 (2017).","journal-title":"Curr. Protoc. Mouse Biol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01407-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01407-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01407-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:06:46Z","timestamp":1776060406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01407-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01407-x","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}